BrP-LPA acts as both an Autotaxin inhibitor (94% inhibition at 10 mM) and pan LPA receptor antagonist (LPA1: 1.5 mM, LPA2: 1.4 mM, LPA3: 1.2 mM, LPA4: 0.27 mM). BrP-LPA inhibits the invasiveness of NIH3T3 ras ATX cells by 40% and decreases chemotaxis by 23%.. BrP-LPA reduces the size of breast (MDA-MB-231), colon (HCT-116) and melanoma (B16F10) tumors in mouse models. PPARg is not activated by BrP-LPA |
